Skip to main content
. 2021 Jul 20;12(15):1555–1563. doi: 10.18632/oncotarget.27973

Figure 1. Differentiation of IMiDs and CELMoDs.

Figure 1

Shown are structures of IMiDs and CELMoDs in myeloma clinical development. Mechanism of action differentiation is primarily derived from the physical interactions with the CRBN/DDB1 complex that may exert regulation of unique and overlapping substrate preference and degradation kinetics and modulation of distinct cell types.